Home » Stocks » ChemoCentryx

ChemoCentryx, Inc. (CCXI)

Stock Price: $57.43 USD 2.45 (4.46%)
Updated Oct 23, 2020 12:42 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 3.96B
Revenue (ttm) 76.08M
Net Income (ttm) -29.81M
Shares Out 68.89M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $57.43
Previous Close $54.98
Change ($) 2.45
Change (%) 4.46%
Day's Open 55.20
Day's Range 55.04 - 57.65
Day's Volume 309,542
52-Week Range 7.50 - 65.43

More Stats

Market Cap 3.96B
Enterprise Value 3.50B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 68.89M
Float 52.53M
EPS (basic) -0.52
EPS (diluted) -0.50
FCF / Share -1.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.48M
Short Ratio 8.04
Short % of Float 10.42%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 52.01
PB Ratio 9.43
Revenue 76.08M
Operating Income -31.49M
Net Income -29.81M
Free Cash Flow -85.41M
Net Cash 452.92M
Net Cash / Share 6.57
Gross Margin -44.89%
Operating Margin -41.39%
Profit Margin -39.20%
FCF Margin -112.27%
ROA -5.10%
ROE -12.10%
ROIC -19.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$76.75*
(33.64% upside)
Low
63.0
Current: $57.43
High
100.0
Target: 76.75
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue36.1342.8882.5011.94--6.065.4231.6734.86
Revenue Growth-15.74%-48.03%591.22%---11.83%-82.89%-9.14%-
Gross Profit36.1342.8882.5011.94--6.065.4231.6734.86
Operating Income-58.30-40.2716.49-40.72-47.69-47.40-39.12-39.63-4.30-5.96
Net Income-55.49-37.9717.86-39.96-47.31-46.93-38.67-39.89-4.62-3.10
Shares Outstanding56.9049.8148.4146.4343.8943.2840.9235.414.214.08
Earnings Per Share-0.98-0.760.36-0.86-1.08-1.08-0.95-1.13-1.10-0.76
Operating Cash Flow-70.1216.444.8839.15-39.33-34.32-33.32-32.233.4218.64
Capital Expenditures-0.79-0.84-0.72-0.30-0.22-0.35-0.55-0.47-0.17-1.19
Free Cash Flow-70.9115.604.1638.84-39.55-34.67-33.87-32.703.2517.44
Cash & Equivalents17317712711871.2873.3613310389.4981.58
Total Debt20.3519.694.68---0.330.9011.921.28
Net Cash / Debt15215712311871.2873.3613310277.5780.29
Assets20918318915678.1611715212210298.13
Liabilities1431691101065.658.387.1111.9825.5521.36
Book Value66.0014.7479.2749.8972.5110914511076.0076.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ChemoCentryx, Inc.
Country United States
Employees 82
CEO Thomas J. Schall

Stock Information

Ticker Symbol CCXI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CCXI
IPO Date February 8, 2012

Description

ChemoCentryx, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.